Table 1.
Baseline characteristics and anti-SARS-CoV-2 antibody responses in SAARD patients and controls.
| FEATURES | SAARD Patients N = 605 (%) | Controls N = 116 (%) |
P-value |
|---|---|---|---|
| Demographics | |||
| Female | 432 (71.40) | 69 (59.48) | 0.0106 |
| Age, median (min-max), years | 58 (16–91) (600*) | 72 (24–90) | <0.0001 |
| Comorbidities | |||
| Diabetes mellitus | 58/598* (9.69) | 25 (21.55) | 0.0004 |
| Cardiovascular Disease | 96/598* (16.05) | 51 (43.96) | <0.0001 |
| Type of vaccine | |||
| Pfizer BioNTech BNT162b2 | 572 (94.54) | 87 (75) | <0.0001 |
| Moderna mRNA-1273 SARS-CoV-2 | 33 (5.45) | 29 (25) | <0.0001 |
| Other vaccines | |||
| Influenza | 528/591* (89.34) | 69 (59.48) | <0.0001 |
| Pneumococcus | 494/591* (83.58) | 45 (38.79) | <0.0001 |
| Treatment modifications | 222 (36.69) | N/A | N/A |
| Extended modifications | 118 (19,50) | N/A | N/A |
| Partial modifications | 104 (17,19) | N/A | N/A |
| Immune response to SARS-CoV-2 vaccines | |||
| Positive | 535 (88.42) | 116 (100) | <0.001 |
Abbreviations: *: Available data; N/A: Not applicable; Treatment modifications: as described in Materials and Methods.